Solid Biosciences Inc (NASDAQ:SLDB) Receives Average Rating of “Hold” from Brokerages
Solid Biosciences Inc (NASDAQ:SLDB) has been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $9.83.
A number of brokerages have commented on SLDB. Leerink Swann upgraded shares of Solid Biosciences from a “market perform” rating to an “outperform” rating in a report on Monday, August 19th. Citigroup cut Solid Biosciences from a “neutral” rating to a “sell” rating and set a $6.00 price target on the stock. in a research note on Thursday, August 29th. Evercore ISI began coverage on Solid Biosciences in a report on Friday, October 11th. They issued an “outperform” rating and a $22.00 price target for the company. Chardan Capital upgraded Solid Biosciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $7.50 to $10.00 in a research note on Friday, August 16th. Finally, Svb Leerink upgraded Solid Biosciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $8.00 to $15.00 in a report on Monday, August 19th.
Several hedge funds have recently modified their holdings of the company. Atria Investments LLC bought a new position in Solid Biosciences during the second quarter worth $472,000. Quantamental Technologies LLC bought a new position in shares of Solid Biosciences in the 2nd quarter worth about $42,000. Cubist Systematic Strategies LLC acquired a new position in shares of Solid Biosciences in the 2nd quarter valued at about $70,000. Capital Fund Management S.A. acquired a new position in shares of Solid Biosciences in the 2nd quarter valued at about $107,000. Finally, Parametric Portfolio Associates LLC acquired a new position in shares of Solid Biosciences in the 2nd quarter valued at about $109,000. 69.85% of the stock is currently owned by institutional investors and hedge funds.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Recommended Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.